Posts tagged “BDSI”

August 23

Premium Lock Longtime BioDelivery Sciences CEO Mark Sirgo is retiring

Dr. Mark Sirgo is stepping down as president anc CEO of Raleigh-based BioDelivery Sciences International. He's held the job since 2005.

BDSI pipeline BDSI pipeline

August 10

Premium Lock Earnings: BDSI tops Street revenue forecast but loss larger than expected

BDSI BioDelivery Sciences reports more revenue than expected by Wall Street but its losses exceed expectations. Overall, the quarterly financial report gave BDSI shares a lift Wednesday.

April 3

Premium Lock BioDelivery Sciences receives more patent protection for drug portfolio

​BioDelivery Sciences International has received two new patents were granted extending patent protection around three of its Food and Drug Administration approved products.

BDSI portfolio BDSI portfolio

Tags: BDSI
Updated March 20

Premium Lock Biotech news: BioDelivery loss worse than forecast; Patheon revenues surge; Tenax, Heat Bio face delisting

Biotech     BioDelivery Sciences reports a loss worse than expected; revenues grow at Patheon; and two Triangle biotech firms face the threat of delisting.

Updated August 13, 2015

Premium Lock With FDA approval in hand, Raleigh drug firm BDSI looks for partners

BioDelivery Sciences has received approval from the Food and Drug Administration for a new formulation of its treatment targeting breakthrough cancer pain. Now the company wants to find a partner to commercialize it.

How BDSI technology works How BDSI technology works

Updated August 13, 2015

Premium Lock Wilmington network adds crowdfunding; BDSI hires Salix execs; Facebook dumps intern; $200M for Vox; Rdio adds 500 stations

Bulldog Bulletin In today's wrapup of technology and life science news: Wilmington-based Connected Investors adds crowdfunding for real estate; Raleigh-based BDSI hires two Salix execs; Facebook dumps an intern turned critic; Vox lands $200 million from NBC Universal; and Rdio adds 500 stations.

Updated June 2, 2015

Premium Lock BDSI borrows $21M; Intel's $17B buy; BlackBerry, Typo settle; Avago acquires Broadcom; Google's free storage

Bulldog In today's Bulldog wrapup of technology and life science news: Raleigh-based BioDeliverySciences raises $21 million in new debt; Intel to acquire chip designer Altera; BlackBerry settles with Ryan Seacrist's Typo; Avago pays $37B for Broadcom; and Google offers free storage for photos, videos.

Updated March 31, 2015

Premium Lock Praise for SciQuest; BDSI shares tumble; Scynexis loss; Amazon's referrals; PlayStation gets Spotify

Bulldog In today's Bulldog wrapup of technology and life science news: SciQuest receives good news from a research firm; BDSI stop drops 24 percent on drug trial news; Scynexis posts a $4.2 million loss; Amazon launches its own referral service; and the PlayStation network embraces Spotify.

February 23, 2015

Premium Lock FDA news means $10M payday for BioDelivery Sciences

Raleigh-based BioDelivery Sciences will receive a $10 million milestone payment from partner Endo Pharmaceuticals now that the FDA has accepted a new drug application for the severe pain reliever system known as Belbuca.

How BDSI technology works How BDSI technology works

Updated January 28, 2015

Premium Lock Apple's blowout quarter; ChannelAdvisor adds Jet; AT&T revenue up 4%; BDSI to relaunch pain drug; Snapchat's media deal

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Apple reports a blowout quarter; ChannelAdvisor adds new service; AT&T grows revenue but books $4B loss; BDSI to relaunch pain treatment; Sanpchat to show media news.

June 9, 2014

Premium Lock BioDelivery Sciences could soar with FDA approval of Bunavail

More than two million people suffer from opioid dependence in the United States. BioDelivery's FDA approval for Bunavail may open up tremendous revenue streams for the Raleigh-based drug company.

How BDSI technology works How BDSI technology works

March 27, 2014

Premium Lock BioDelivery Sciences picks Quintiles to help launch proposed drug

Raleigh-based BioDelivery Sciences recently raised $60 million to help commercialize its proposed chronic pain reliever drug and hopes to win FDA approval for it in June. On Thursday, BDSI said it had chosen Durham-based Quintiles, the world's largest life science services firm, to help take the drug to market. The deal includes formation of a sales force.

How BDSI technology works How BDSI technology works

Updated February 10, 2014

Premium Lock Pain drug firm BioDelivery Sciences raising $60M in stock sale

BDSI Capitalizing on news that its chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, BioDelivery Sciences International is raising $60 million to finance commercialization efforts.

January 24, 2014

Premium Lock Pain drug from BDSI shows positive trial results, triggers $10M milestone

BDSI Chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, and securing trial data for further analysis has triggered a $10 million milestone to BioDelivery Sciences International.

December 3, 2013

Premium Lock BDSI hires key sales executive ahead of expected 2014 drug launch

BDSI's drug pipeline BioDelivery Sciences International's opioid dependence treatment Bunavail faces an FDA decision date of June 7 and the Raleigh company is getting ready to go to market if it secures regulatory approval.

Updated December 2, 2013

Premium Lock BioDelivery Sciences targets more tests for neuropathy treatment after 'positive' FDA meeting

Diabetes BioDelivery Sciences invested a mix of stock and cash that could total nearly $40 million if a proposed gel to treat diabetic neuropathy pain wins FDA approval, and the company says it will proceed with further tests after a "positive" meeting with regulators.

Updated October 21, 2013

Premium Lock BioDelivery Sciences names new chief financial officer

BDSI The Raleigh-based firm says its current CFO Jim McNulty will assume a new role as senior vice president for finance and treasurer.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith